TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch

Benzinga Logo Benzinga By Vandana Singh
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch

The FDA is considering expediting the review process for Eli Lilly's experimental oral weight-loss treatment, orforglipron, potentially moving the decision date to late March. Rival Novo Nordisk is preparing to launch its own weight-loss pill in December or January.

Insights
OXY.WS   positive

Berkshire agreed to acquire OxyChem's petrochemical unit for $9.7 billion


LLY   positive

Potential for faster FDA review and accelerated market entry for their weight loss drug